Research programme: cancer therapy - OncoTherapy/Shionogi

Drug Profile

Research programme: cancer therapy - OncoTherapy/Shionogi

Latest Information Update: 04 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoTherapy Science; Shionogi
  • Class Cancer vaccines; Peptide vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Head and neck cancer; Lung cancer
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 30 Mar 2012 OncoTherapy Science and Shionogi expand their research collaboration for peptide cancer vaccines
  • 14 Feb 2011 Preclinical development is ongoing in Japan
  • 26 Mar 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top